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Abstract We conducted an economic evaluation in a UK setting based on a12-week prospective randomized open-
labelparallel-group comparison of eformoterol Turbohalers12 mgb.i.d. with salmeterol Accuhalers 50 mgb.i.d. inchil-
dren aged 6--17 with symptomatic asthma receiving inhaled corticosteroids and short-acting b2-agonists.The principal
effectivenessmeasurewaspercentageofsymptom-freedayswithno short-acting b2-agonistuseduring the studyperiod.
Asthma-relatedmedication, unscheduled physician contacts and hospitalizationswere collected prospectively and cost
tothe UKNHScalculatedusing year 2000 prices.The economicevaluationincluded 73 patientsinthe eformoterolgroup
and 72 patients in the salmeterolgroup. Themean age of patientswas11?6 years (eformoterol) and11?8 years (salmeter-
ol).Themean percentage of symptom-free dayswith no short-acting b2-agonist use was 39% in the eformoterol group
and 30% in the salmeterol group.Meanper patientdaily cost was d1?15 in the eformoterol group and d1?39 in the salme-
terolgroup.Both cost and effectiveness differences favoured eformoterol (Po0?05; one-sided).Sensitivity analysis con-
firmed the results to be robust to changes in effectiveness, price and resource utilisation parameters. Eformoterol
delivered byTurbohalerswas found to be significantlymore effective and less expensive than salmeterol Accuhalers
in this study.r2002 Harcourt Publishers Ltd
doi:10.1053/rmed.2001.1258, available online athttp://www.idealibrary.comon
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Paediatric asthma is one of themostprevalent childhood
illnesses and in theUKasmany as1in 7 childrenbetween
the ages of 2 and15 havebeen diagnosedwith the disease
(1).The UK has one of the highest rates of asthma in the
world and prevalence continues to rise (1).Childrenwith
poorly controlled asthma experience substantial mor-
bidity and the problems of asthma include reduced qual-
ity of life, disruption of education and adverse impact on
carer wellbeing (2). Although asthma-related mortality
has fallen substantially, children continue to die from
poorly controlled severe asthma in the UK (3).
The British Thoracic Society (BTS) guidelines form the
mainstay of asthma management in the UK, with one
survey of adultsmanaged in primary care reporting that
91% of patients received treatment within a recognisedReceived 30May 2001and accepted in revised form13November 2001.
Correspondence shouldbe addressed to: Jonathan Plumb,AstraZeneca
UKLtd,Horizon Place,CapabilityGreen,Luton, Bedfordshire,LU13LU,
UK.step of the guidelines (4). The BTS guidelines divide the
management of asthma into di¡erent steps depending
on the treatment required to achieve control, and re-
commend frequent review with the aim of stepwise re-
duction in treatment if possible (5).The goals of therapy
include minimising or eliminating symptoms (including
nocturnal symptoms) and exacerbations, and achieving
minimumuse of rescuemedication (short-acting b2-ago-
nists) as well as improving lung function (5). For patients
where control of asthma is not achieved with moderate
doses of inhaled corticosteroids (for example, beclome-
tasone or budesonide100^400mg b.i.d.), therapy should
be stepped up to either high-dose inhaled corticoster-
oids or low-dose inhaled corticosteroids and a long-act-
ing b2-agonist (5).
Although the risk^bene¢tof inhaled corticosteroids is
well accepted, there is evidence that all inhaled corticos-
teroids are absorbed to some extent from the lung (6).
Concerns exist about the long-term e¡ects of high-dose
inhaled corticosteroids on bone mineral density, catar-
acts, glaucoma and glucose tolerance in adults (6)
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Interest therefore exists in obtaining good asthma con-
trol at the lowest possible inhaled corticosteroid dose
(5).The addition of a long-acting b2-agonist o¡ers an al-
ternative to increased doses of inhaled corticosteroids
(5). Until recently, salmeterol was the only long-acting
b2-agonist licensed for use in children (10). However, re-
cent results have shown that eformoterol is well-toler-
ated and e⁄cacious in children (11, 12) and is now
indicated for use in children aged 6 and above.
The UK National Health Service (NHS) operates
within a limitedbudget and resources are scarce.The to-
tal cost of asthma treatment in theUKis estimated to be
in excess of d2 billion per year with prescription costs
accounting for a substantial proportion of this ¢gure (1).
Given the high prevalence of childhood asthma, the po-
tential cost of introducing new treatments in this area
may be substantial and it is important to demonstrate
that any new treatment is a cost-e¡ective use of limited
NHS resources.
To examine the cost-e¡ectiveness of introducing efor-
moterol for the management of asthma in children, we
conducted an economic evaluation based on a recent
study of eformoterol Turbohalers 12mg b.i.d. vs. salme-
terol Accuhalers 50mg b.i.d. in children (the FACT
study). The study methodology, e⁄cacy and safety re-
sults have recently been reported separately (13).
METHODS
Study design
We conducted a cost-e¡ectiveness evaluationbased on a
randomizedprospectivemulti-centre open-label parallel
group study conducted in general practice in theUK and
the Republic of Ireland (the FACT study). The study en-
rolled patients aged 6^17 years with a clinical diagnosis
of asthma, currently managed with short-acting b2-ago-
nists and an inhaled corticosteroid, who were still ex-
periencing asthma symptoms such as chest tightness,
cough, wheeze or shortness of breath on more than 3
days or nights a week. Patients were randomized to re-
ceive eformoterol Turbohalers12mg b.i.d. or salmeterol
Accuhaler/ Diskuss 50mg b.i.d. in addition to their usual
medication for a period of 12 weeks. Patients attended
the clinic 4, 8 and12 weeks after randomization.
The primary e⁄cacy endpoint in the FACTstudy was
reduction in short-acting b2-agonist usage in the 7 days
prior to theweek12 clinic visit. Secondary endpoints in-
cluded symptom measures, peak expiratory £ow (PEF),
poorly controlled days and quality of life. Two quality of
life questionnaires were used in the study, the Paediatric
Asthma Quality of Life Questionnaire (PAQLQ), com-
pletedby the patient, and the Paediatric AsthmaCaregi-
ver’s Quality of Life Questionnaire (PACQLQ),
completed by the parent/guardian.Patients
The economic evaluation included all patients enrolled in
the FACTstudy at the UK centres who met the criteria
for e¡ectiveness analysis below. Patients recruited in the
Republic of Ireland (n=6) were excluded from the eco-
nomic evaluationbefore analysis began.Medical resource
use and cost is dependent upon the setting of care, and
unit costs and treatment practice may not be the same
for the Republic of Ireland as for the UK.
E¡ectivenessmeasures
For the economic evaluation, the main e¡ectiveness
measureusedwas thepercentage of ‘‘symptom-freedays
with no short-acting b2-agonist use’’, de¢ned as days on
which:
K both day-time and night-time symptom scores were
recorded as zero in the patient’s diary card,
K no nocturnal awakenings due to asthma were
recorded and
K short-acting b2-agonist usewas recorded as zero.
The percentage of symptom-free days with no short-
acting b2-agonist use was calculated for each patient by
dividing thenumberof symptom-free dayswith no short-
acting b2-agonist use by the number of evaluable days.
Evaluable days were de¢ned as days on which day and
night-time symptoms, nocturnal awakening and short-
acting b2-agonist usewere all recorded in the diary card.
Resource use
Data on resource use were collected prospectively dur-
ing the trial. Parameters collected were: study medica-
tion use, short-acting b2-agonist use, number of
unscheduled General Practitioner (GP) visits, asthma-
relatedhospitalizations, use of severe exacerbationmed-
ication (courses of oral corticosteroids) and use of rele-
vant concomitantmedications including all prescriptions
recordedby the investigators as asthma-relatedmedica-
tion. The number of inhalations of short-acting b2-ago-
nist was collected in diary cards, and other measures
were consistently recorded in a case report form
(CRF).GP visits mandated by the protocol were consid-
ered to be atypical of ordinary asthma management and
excluded from the analysis. Patients whowithdrew early
from the study were asked to return for a follow-up visit
at week 12 and the resource use parts of the CRF were
completed.We calculated the number of days for which
each recorded asthma-related concomitant medication
was used as the di¡erence between start and stop dates
in the CRF.The number of days of study medication use
was calculated to be the number of days for which the
patient was randomized in the study.
252 RESPIRATORYMEDICINECosts
Per patient costs were calculated by multiplying the
number of resourceunitsby theunit cost of the resource
used. Unit costs were taken from published sources,
using the most recently available prices at the time of
analysis (December 2000) (10,14).The costof hospitaliza-
tions was not calculated, as no asthma-related hospitali-
zations or Accident and Emergency attendances were
reported in this study. Since this study was conducted
in primary care, the cost of a physician contact was esti-
mated to be the cost of a GP visit. When drug doses
were not recorded in the patient’s CRF, the cost used
was that of themean daily starting dose in the 2000 Brit-
ish National Formulary (10). Per patient daily costs were
calculated by dividing the total per patient cost by the
number of days from the start of the study to the com-
pletion of the ¢nal visit.Costs were calculated from the
perspective of the UKNHS.
Analysis
Missing Data
The analysis excluded all patients with less than 7 days of
evaluable e¡ectiveness data (n=4). Patients who with-
drew early through lack of e¡ect or an adverse event
were taken to be treatment failures and the percentage
of symptom-free days was calculated as the number of
symptom-free days observed while the patient was in-
cluded in the study divided by the number of days be-
tween the date of enrolment and the planned date of
the ¢nal visit.For patients whowithdrew early for other
reasons, we calculated the percentage of symptom-free
days by dividing the number of symptom-free days ob-
served before the patient withdrew by the number of
evaluable days before the patient withdrew from the
study. Resource use data were not adjusted for patients
whowithdrewearly, as resourceuse datawere collected
for all patients at the end of the12-week period irrespec-
tive of clinical trial completion. Daily use of short-acting
b2-agonists by patients who did not complete the study
was calculated as themean rate of use recorded in diary
cards during the period that patients were enrolled in
the study.
Cost-e¡ectiveness Ratios
Mean cost-e¡ectiveness ratios were calculated for each
group by dividing the mean per patient daily cost by the
meanpercentage of symptom-free dayswith no short-act-
ing b2-agonist use.The incremental cost-e¡ectiveness ra-
tio (ICER)was calculatedbydividing the di¡erence inmean
per patient daily cost (eformoterol armsalmeterol arm)
by the di¡erence in mean percentage of symptom-free
days with no short-acting b2-agonist use (eformoterolarmsalmeterol arm).The incremental cost-e¡ectiveness
ratio estimates the balance between costs and bene¢ts
achievedwhen comparing two therapies.
Uncertainty
Con¢dence intervals around per patient daily cost, e¡ec-
tiveness measures and the ICER were generated using
non-parametricbootstrapreplication (15). Statistical signif-
icancewas de¢ned as Po0?05 in a one-tailed comparison.
Sensitivityanalyses
Sensitivity analysiswas conducted to determinewhether
the results are robust to changes in the e¡ectiveness
measure. Two alternative e¡ectiveness measures were
de¢ned:
K Sensitivity test1: Symptom-free day
Day and night-time symptoms = 0; no restriction on
short-acting b2-agonist use (to re£ect the possibility
of conditioned prophylactic use); no nocturnal
awakening
K Sensitivity test 2: Successfully controlled day
PEF4 80% of baseline;o 4 inhalations short-acting
b2-agonist above baseline; no nocturnal awakening
Cost-e¡ectiveness ratios were calculated for each of the
sensitivity tests.
Variation in resource use was addressed by the boot-
strapping analysis.Moreover, since drug costs accounted
for themajority of total costs and drug prices in the UK
are ¢xed in the primary care setting, we do not report
additional sensitivity analyses addressing unit costs.
Budget impact estimates
We conducted additional analyses to estimate the im-
pact of introducing eformoterol for the management of
childrenwith asthma on the budget of a typical GP prac-
tice, Primary Care Group (PCG) and Health Authority
(HA). The eligible population was estimated to be the
number of children in the appropriate age group who
are currently managed at Step 3 of the BTS guidelines,
as the entry criteria for the treatments in this study cor-
respond to recommended therapy for children at BTS
Step 3 (5). The prevalence of Step 3 paediatric asthma
was estimated using published information on the popu-
lation prevalence of asthma (1) multiplied by the percen-
tage of asthmatics at step 3 in the BTS guidelines (16).
Estimated prevalence was multiplied by the population
covered in a typical practice/authority (17,18) to estimate
the number of eligible children. The number of eligible
children was multiplied by the annual costs of manage-
ment using eformoterol or salmeterol as calculated in
this study. The di¡erence between projected aggregate
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eligible children were switched from salmeterol to efor-
moterol.
RESULTS
Clinical results
The e⁄cacy and safety results of this study are reported
separately (13).Both drugswerewell tolerated and signif-
icantly improved; asthma symptoms, children and par-
ent/guardian quality of life and total use of short-acting
b2-agonists at 4, 8 and12 weeks.Compared with salme-
terol, eformoterol signi¢cantly reduced short-acting b2-
agonist use at 8 and 12 weeks (P=0?04), nocturnal
wheeze at 8 weeks (P=0?03) and nocturnal symptoms
at12 weeks (P=0?05).
No serious adverse events related to studymedication
were observed, and both therapies were generally well
tolerated.
Patients included in economic evaluation
Onehundred and forty-¢vepatientswere includedin the
economic evaluation, 73 in the eformoterol group and 72
in the salmeterol group. The mean age of patients was
11?6 years (eformoterolgroup) and11?8 years (salmeterol
group). Slightly more patients in the eformoterol than
the salmeterol groupweremale (60% vs. 50%), but other
demographic parameters were similar in the two treat-
ment groups (Table1).
E¡ectivenessmeasure
In the primary evaluation of the e¡ectiveness data, the
mean percentage of symptom-free days with no short-TABLE1. Demographic information
Treatmentgroupw
N
Mean age, years (SD)
% male
Meanheight, cm (SD)
Meanweight, kg (SD)
Duration of asthma, n (%)
o1year
X1,o5yrs
X5,o10yrs
X10 years
Type of asthma, n (%)
Intrinsic
Extrinsic
Unspeci¢ed
wStudypopulationused for the economic evaluation^intentioacting b2-agonistusewas 39% for the eformoterol group
and 30% for the salmeterol group.The mean number of
evaluable days per patient was 72 for the eformoterol
groups and 74 for the salmeterol group.
The bootstrap replications found that the percentage
of symptom-free days with no short-acting b2-agonist
use was higher in the eformoterol group in 96?6% of
cases, and higher in the salmeterol group in 3?4% of
cases.
Resource use
Mean and total resource use for each group are shown in
Table 2.The number of days of studymedication usewas
similar in the two groups, but short-acting b2-agonist
and concomitant medication use were both numerically
higher in the salmeterol group. Unscheduled GP visits
and use of severe exacerbation medications were infre-
quent.Nopatients in this studyreported asthma-related
hospitalizations.
Per patient daily cost
Per patient daily cost is shown inTable 3.The mean daily
costwas d1?39 for the salmeterol group and d1?15 for the
eformoterol group (Po0?001).The majority of cost was
accounted for by study medication and relevant conco-
mitant medication. Both of these costs were higher in
the salmeterolgroup than the eformoterolgroup. Severe
exacerbationmedication andGP visitsmade a small con-
tribution to the overall cost.
Cost-e¡ectiveness ratios
The estimatedmean cost-e¡ectiveness ratio for eformo-
terol was d2?97 per symptom-free day compared toEformoterol Salmeterol
73 72
11.6 (3.0) 11.8 (2.8)
60 50
147 (18) 149 (15)
43?4 (17?1) 47?7 (19?7)
2 (3) 5 (7)
20 (27) 20 (28)
31 (42) 34 (47)
20 (27) 13 (18)
22 (30) 18 (25)
22 (30) 22 (31)
29 (40) 32 (44)
nto treatexcluding Republic of Irelandpatients.
TABLE 2. Resource use
Treatmentgroupw Eformoterol Salmeterol
n 73 72
Days studymedicationusage
Total 5584 5791
Mean (SD) 76 (19) 80 (15)
Range 12^99 23^102
Short-acting b2-agonistusage (numberof inhalations)
Total 7936 11823
Mean (SD) 109 (145) 164 (178)
Range 0^914 0^760
Unscheduled GP visits
Total 4 1
Mean (SD) 0?05 (0.23) 0?01 (0?12)
Range 0^2 0^1
Use of severe exacerbationmedications (oral corticosteroid courses)
Total 2 0
Mean (SD) 0?03 (0?16) 0 ()
Range 0^1 0^0
Relevantconcomitantmedications (days used)z
Total 5455 6003
Mean (SD) 75 (24) 83 (29)
Range 1^135 1^255
wStudypopulationused for the economic evaluation^intentionto treatexcluding Republic of Irelandpatients.
zMayexceednumberof days in studyifmore than onemedicationwas taken on same day.
TABLE 3. Per patientdailycost
Treatmentgroupw Eformoterol Salmeterol Increment
n 73 72
Per patientdailycostof studymedicationusage (d)
Mean (SD) 0?83 (0?00) 0?95 (0?00) 0?13
Range 0?83,0?83 0?95,0?95
Per patientdailycostof short-acting b2-agonistusage (d)
Mean (SD) 0?06 (0?08) 0?07 (0?10) 0?02
Range 0?00,0?40 0?00,0?51
Per patientdailycostof unscheduled GP visits (d)
Mean (SD) 0?02 (0?08) 0?00 (0?03) 0?01
Range 0?00, 2?00 0?00,0?30
Per patientdailycostof severe exacerbationmedications (d)
Mean (SD) 0?00 (0?00) 0?00 (0?00) 0?00
Range 0?00,0?02 0?00,0?00
Per patientdailycostof relevantconcomitantmedications (d)
Mean (SD) 0?26 (0?18) 0?36 (0?30) 0?10
Range 0?00,1?11 0?00,1?55
Totalper patientdailycost (d)
Mean (SD) 1?15 (0?22) 1?39 (0?35) 0?24**
Range 0?85,1?97 0?98, 2?53
95% CI 1?11,1?21 1?32,1?47
Con¢dence intervals derivedusingnon-parametric bootstrapping.
wStudypopulationused for the economic evaluation^intentionto treatexcluding Republic of Irelandpatients.
**Po0?001.
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mated ICER was negative, re£ecting the fact that efor-
moterol was less costly and more e¡ective than
salmeterol.Con¢dence intervals around the ICERs were
generatedusing non-parametric bootstrapping.The cost
and e¡ectiveness estimates generated by the boot-
strappedreplications are shown in Fig.1.Ninety-six point
six percent of replications are in the bottom right quad-
rant of the cost-e¡ectiveness plane, indicating both low-
er cost and improved e¡ectiveness for eformoterol
compared to salmeterol.
Sensitivity analyses
Repeating the cost-e¡ectiveness calculations using
symptom-free days with no restriction on short-acting
b2-agonist use as a measure of e¡ectiveness (sensitivity
test 1) also found eformoterol to be signi¢cantly more
cost-e¡ective than salmeterol. The second sensitivity
test (successfully controlled days) found higher success
rates for both groups, and the di¡erence between
groups did not achieve statistical signi¢cance.
The ¢rst sensitivity test con¢rmed that the ¢nding of
higher cost-e¡ectiveness ratios is robust to changes in
the de¢nition of symptom-free day used.For the second
test (successfully controlled days), there was a trend to-
wards lower cost-e¡ectiveness in the eformoterol group
but this did not achieve statistical signi¢cance (Table 4).
Budget impact analyses
Our analysis (Table 5) suggests that in children aged 6^17
years, using eformoterol in preference to salmeterolPrimary effectiveness measure: symptom-free day
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FIG. 1. Cost-e¡ectiveness bootstrap replications.Primary e¡ectiv
nist use.would result in a potential annual cost saving of d85?89
per patient.Thus, using eformoterol in preference to sal-
meterol would reduce costs:
K By d3092 per year for an average GP practice list of
6143 patients, of whom we estimate that 36 would
meet the entry criteria for the trial;
K By d52 822 per year for a PCG with a patient
population of 105 808, of whomwe estimate that 615
would be eligible; and,
K By d248 909 for a health authority managing a
population of 498 961, of whom we estimate that
2898 would be eligible.
DISCUSSION
This study found that, in children with symptomatic
asthma who were receiving short-acting b2-agonists
and inhaled corticosteroids, treatmentwith eformoterol
was signi¢cantly more e¡ective and signi¢cantly less ex-
pensive than treatment with salmeterol (P=0?034 and
Po0?001 in one-sided comparisons). These results are
consistent with the ¢ndings of the primary clinical eva-
luation, where eformoterol signi¢cantly reduced short-
acting b2-agonist use at 8 and 12 weeks (P=0?04), and
nocturnal symptoms at 12 weeks (P=0?05) compared
with salmeterol (13). Although previous work has com-
pared the cost-e¡ectiveness of these two drugs in adults
with asthma (19), this is the ¢rst time the comparisonhas
been reported in children. Previous cost-e¡ectiveness
studies in the UK (20) and as part of a six-country Eur-
opean study (19) reported signi¢cantly lower medicals with no short-acting 2-aganist use
15 20 25 30
s (% success)
Salmeterol
less expensive
Eformoterol
less effective
enessmeasure: symptom-free dayswith no short-acting b2-ago-
TABLE 4. Results of sensitivity tests
Meancost-e¡ectiveness ratios
Treatmentgroupw Eformoterol Salmeterol Incremental (CIz)
Primarycomparison:
Costper symptom-free daywithno short-acting b2-agonistuse 2?97 4?69 2?50
(11?8,1?0)
Sensitivity test1:
Dayandnight-time symptoms = 0; no nocturnal awakening 2?18 3?28 2?22
(7?2,1?0)
Sensitivity test 2:
PEF4 80% of baseline;o4 inhalations short-acting
b2-agonist above baseline; no night awakening
1?37 1?76 4?42
(21?4,15?7)
Con¢dence intervals derivedusingnon-parametric bootstrapping.
wStudypopulationused for the economic evaluation^intentionto treatexcluding Republic of Irelandpatients.
z90% con¢denceintervals.A 90%CIthatliesentirelybelowzero signi¢es a signi¢cantdi¡erence at Po0?05 inbothcosts and
e¡ectiveness in a one-tailed comparison.
TABLE 5. Estimated budget impact
Treatmentgroupw Eformoterol Salmeterol Increment
Expected annual cost per patient (d) 421?14 507?03 85?89
Population aged 6^17 (%) 15?5 15?5
Prevalence of Step 3 asthma in children aged 6^17z (%) 3?8 3?8
Average GPpractice list size (n) 6143 6143
Numberof children eligible (n) 36 36
Annual expenditure (d) 15161 18253 3092
Average PCG population (n) 105 808 105 808
Numberof children eligible (n) 615 615
Annual expenditure (d) 259 004 311826 52822
Average Health Authoritypopulation (n) 498 961 498 961
Numberof children eligible (n) 2898 2898
Annual expenditure (d) 1220 476 1469385 248 909
Population statistics (17), list sizes (18), prevalence data (1,16).
wStudypopulationused for the economic evaluation^intentionto treatexcluding Republic of Irelandpatients.
zThis value is an estimate basedupon data froma sample of children aged 5^15.
256 RESPIRATORYMEDICINEcost with eformoterol than with salmeterol, although
the European studydid notreport statistical signi¢cance
when non-medical cost such as work time lost was also
included (19).
The choice of suitable endpoints for cost-e¡ectiveness
studies in asthma is controversial and endpoints used in
previous studies include episode-free days (EFDs) (19, 21),
successfully-treated weeks (STWs) (22) and symptom-
free days (SFDs) (20, 22, 23). In addition to the use of
SFDs as an endpoint in studies, this measure is also re-
commended in the 1996 US working group report on
the cost-e¡ectiveness of asthma care (24).
The primary clinical endpoint of this study was reduc-
tion in use of inhaled short-acting b2-agonists.However,to be consistent with previous economic evaluations we
wished to use a measure of success that addressed pa-
tient symptoms.ThemeasureusedFsymptom-freedays
with no short-acting b2-agonist useFmodi¢ed the nor-
mal SFD as it additionally required that patients should
have reported zero short-acting b2-agonist use.This re-
£ects the primary clinical endpoint of the study. More-
over, reducing short-acting b2-agonist use is a stated
goal of therapy (5). We also examined symptom-free
days alonewith no restriction on short-acting b2-agonist
use (sensitivity test1).Both productsweremore cost-ef-
fective using symptom-free days alone than in the pri-
mary analysis, although the di¡erence between groups
was maintained. Lower cost-e¡ectiveness ratios were
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agonist use in the absence of asthma symptoms, leading
to the study ¢nding a larger number of symptom-free
days than symptom-free days with no short-acting b2-
agonist use. The reporting of short-acting b2-agonist
use in the absence of symptomsmay re£ect prophylactic
use of thesemedicines.
The measure of ‘‘successfully controlled days’’ used
(sensitivity test 2) also considered lung function. Success
rates based on this measure were found to be higher
than the number of symptom-based days in both groups.
However, measuring lung function did not capture the
impact of the disease on outcomes in this population,
and the study was insu⁄ciently powered to detect a dif-
ference between treatment groups using this measure.
We suggest this illustrates the importance of measuring
patient outcomes in asthma studies in addition to assess-
ments based on lung function.
An unexpected ¢nding in this study was the low rate
of non-drugresourceuse (i.e. hospital care andGP visits)
and the infrequentuse of oral corticosteroids in both pa-
tient groups, showing that severe exacerbationswere in-
frequent in this patient population. The cost ¢ndings of
this study are therefore dominated by the costs of study
and other asthma-related medications. A recent large
retrospective study found non-drug resource use in chil-
drenwith asthmamanaged in the community to be high-
er than in our study (16). A possible explanation for the
good control observed in this study is that e¡ective asth-
ma controlwas establishedwith the drugregimens used.
However, alternative explanations exist. To con¢rm
whether these ¢ndings can be extrapolated to the gen-
eral population, itwouldbenecessary to be able to sepa-
rate the e¡ects of medication taken from the e¡ects of
the study itself. In addition, a follow-up longer than the12
weeks’duration of the study, and con¢rmation of the re-
sults in a larger number of patients would be useful.
This cost-e¡ectiveness study was performed from the
perspective of the UK NHS and in a primary care set-
ting.Medical costs, drugprices andmanagementpractice
di¡er between countries, so the applicability of these re-
sults in other countries should be assessed with caution.
Further analysis would be required to con¢rm the cost-
e¡ectiveness and budget impact ¢ndings in other health
care settings and countries.
Finally it should be noted that the cost savings esti-
mated to di¡erent agents represent an upper limit of
what might be achieved in practice, as we assumed that
all eligible children at BTS Step 3 aremanagedwith long-
acting b2-agonists (salmeterol) at present.
CONCLUSIONS
This cost-e¡ectiveness study found the percentage of
symptom-free days with no short-acting b2-agonist useto be signi¢cantly higher and cost to be signi¢cantly low-
er for children treatedwith eformoterol rather than sal-
meterol in step 3 paediatric asthma.
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